BioLife Solutions, Inc. (BLFS)
After hours:
| Previous Close | 18.01 |
| Open | 17.90 |
| Bid | 19.49 x 400 |
| Ask | 19.58 x 400 |
| Day's Range | 17.70 - 20.89 |
| 52 Week Range | 8.92 - 24.50 |
| Volume | |
| Avg. Volume | 422,587 |
| Market Cap | 885.162M |
| Beta (5Y Monthly) | 1.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.52 |
| Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.13 |
Insider MonkeyBioLife Solutions, Inc. (NASDAQ:BLFS) Q1 2024 Earnings Call Transcript
BioLife Solutions, Inc. (NASDAQ:BLFS) Q1 2024 Earnings Call Transcript May 9, 2024 BioLife Solutions, Inc. beats earnings expectations. Reported EPS is $-0.19, expectations were $-0.26. BLFS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the BioLife Solutions First […]
ZacksBioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Tops Revenue Estimates
BioLife Solutions (BLFS) delivered earnings and revenue surprises of 26.92% and 8.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
PR NewswireBioLife Solutions Reports First Quarter 2024 Financial Results
BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader biopharma markets, today announced financial results for the three months ended March 31, 2024 and affirmed its revenue guidance for 2024.
